Trial Profile

Multicenter,Open-label,Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib + Aromatase Inhibitors for(HR)+/(HER2)-, MBC With Either Germline BRCA-mutated or Germinal BRCA-wildtype and Homologous Recombination Deficiency

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niraparib (Primary) ; Aromatase inhibitors
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms LUZERN

20 Nov 2023 Status changed from discontinued to completed.
17 Jan 2023 Status changed from recruiting to discontinued. Study prematurely terminated due to lack of recruitment. After several screening failures since May 2022, no potential candidate for cohort B was found (gBRCA wild type y HRD score greater than 25 on myChoice CDx PLUS test).
09 Jan 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com